The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Ozempic has officially arrived in India at a comparatively affordable price, sparking buzz among diabetes and weight loss patients alike. Experts break down how it works, who it’s meant for, and the ...

Morgan Stanley said that the company is a distinctive play on shifting lifestyle dynamics, and is largely insulated from ...

Doctors caution that while Ozempic can help manage diabetes and obesity under medical supervision, misuse as a weight-loss ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

The European Medicines Agency (EMA) has recommended extending the use of Mounjaro to younger patients with diabetes, ...